bullish
Insights on China Genetic Testing Industry
366 Views06 Nov 2020 09:55
This article analyzed China genetic testing industry in the perspective of favorable policy, market potential, future trend, investment trend in primary market and related listed companies.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- China Healthcare Weekly (Nov.13)17 Nov 2020
- JOINN Laboratories - Q3 Performance in Line with Expectations; Promising Globalization After HK IPO15 Nov 2020
- Insights on China Healthcare Policy: New Intensive Procurement Policy for High-Value Medical Devices12 Nov 2020
- Insights on China Genetic Testing Industry06 Nov 2020
- JW Therapeutics - Concerns Are in the Short Term but Still Promising in the Long Term28 Oct 2020
- Insights On China Healthcare Policy - 4+7: New Volume-Based Purchasing Policy22 Oct 2020
- A Different Angle - Simcere Pharmaceutical VS Everest Medicines (01952.HK)11 Oct 2020
x